An independent analysis found a 66.7% response rate in 12 patients treated for melanoma spread to the liver.
An independent analysis of 12 patients with liver-metastatic uveal melanoma treated with melphalan hepatic delivery (PHP) and ipilimumab/nivolumab reported a 66.7% response rate and 75% disease control rate. The median overall survival was 28 months. Delcath Systems, Inc. is presenting clinical trial updates at ESMO Congress 2026, including data on its HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy.
How this was made
The 30-second read
Why it matters
First public disclosure of efficacy data for Delcath's liver‑directed melphalan delivery platform, likely to move the stock.
Market read
New trial data provides a material catalyst for Delcath, a US‑listed biotech, potentially influencing its share price.
What to watch
Potential regulatory hurdles and reimbursement challenges for HEPZATO KIT could temper enthusiasm.
Background
The release is a Business Wire announcement summarizing an independent analysis of Delcath's CHEMOSAT PHP system presented at ESMO 2026.
Ticker impact
Delcath Systems reported a 66.7% objective response rate in a retrospective cohort of 12 patients with liver‑metastatic uveal melanoma.
potential upside as the market prices in the strong response rate
The trial results are the first public disclosure of efficacy, a material catalyst for a biotech with a US listing.
Market effects
May boost interest in liver‑directed oncology devices and could benefit peers in hepatic perfusion technologies.
Limited to US biotech investors; no broader regional effect.
Modest, confined to specialty oncology segment.
Counterpoint
The small sample size (12 patients) and early‑stage data may not translate to larger trials, keeping downside risk.
Key entities
- companyDelcath Systems, Inc.
Interventional oncology company developing HEPZATO KIT and CHEMOSAT hepatic delivery system.
